Published

19.3 Psilocybin-Assisted Therapy for MDD: Current Evidence and Clinical Considerations

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of the American Academy of Child & Adolescent Psychiatry
Date: 2022-10-01
Source: OpenAlex
DOI: 10.1016/j.jaac.2022.07.664
PubMed: Unavailable

Authors

Natalie Gukasyan

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Receptor Pharmacology Randomized Controlled Trial Randomized Controlled Trial

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

19.3 Psilocybin-Assisted Therapy for MDD: Current Evidence and Clinical Considerations2022-10-01

Related papers

COMBINATION OF PSILOCYBIN AND COGNITIVE BEHAVIORAL THERAPY IMPROVES OXYTOCIN LEVELS AND DEPRESSIVE SYMPTOMS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDERGenetics and Molecular Research · 2026-01-01 Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?Clinical Pharmacology & Therapeutics · 2023-10-05 Could psilocin rescue chronic, stress-accelerated, transcriptional aging in brain?UKnowledge (University of Kentucky) · 2025-03-04 Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.Expert review of clinical pharmacology · 2018-09-01